Centessa Pharmaceuticals (CNTA) Projected to Post Earnings on Thursday

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Centessa Pharmaceuticals to post earnings of ($0.45) per share for the quarter.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA traded down $0.54 during midday trading on Friday, hitting $15.75. 1,555,582 shares of the stock traded hands, compared to its average volume of 526,428. Centessa Pharmaceuticals has a 1-year low of $7.75 and a 1-year high of $19.09. The firm has a market capitalization of $2.08 billion, a PE ratio of -10.29 and a beta of 1.54. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The business's 50 day moving average price is $16.47 and its two-hundred day moving average price is $16.40.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $17.17, for a total value of $120,190.00. Following the sale, the insider now directly owns 225,007 shares in the company, valued at approximately $3,863,370.19. The trade was a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the sale, the general counsel now owns 118,265 shares in the company, valued at approximately $1,808,271.85. This trade represents a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 260,168 shares of company stock worth $4,316,568. 11.59% of the stock is owned by corporate insiders.

Remove Ads

Analyst Ratings Changes

Several brokerages have recently issued reports on CNTA. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating for the company. Guggenheim restated a "buy" rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Finally, Morgan Stanley restated an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals has an average rating of "Buy" and an average target price of $26.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.